Artiva Biotherapeutics (NASDAQ: ARTV) shares Q2 2026 financial results release
Rhea-AI Filing Summary
Artiva Biotherapeutics, Inc. reported that on August 6, 2026 it issued a press release announcing its financial results for the quarter ended June 30, 2026. The press release is provided as Exhibit 99.1 and describes the company’s performance for that period.
The company explains that the information in this financial results press release, including Exhibit 99.1, is being furnished under the Exchange Act and is not deemed “filed” for purposes of Section 18 or automatically incorporated into other Securities Act or Exchange Act documents unless expressly stated. Artiva’s common stock trades on the Nasdaq Global Market under the symbol ARTV, and it is identified as an emerging growth company.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Terms
Emerging growth company, Section 18 of the Securities Exchange Act of 1934, incorporated by reference, Inline XBRL
4 terms
Emerging growth company regulatory
"Emerging growth company status under Rule 405 of this chapter"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Section 18 of the Securities Exchange Act of 1934 regulatory
"shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934"
incorporated by reference regulatory
"nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933"
Inline XBRL technical
"Cover Page Interactive Data File (embedded within the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
Earnings Snapshot
quarter ended June 30, 2026
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Artiva Biotherapeutics (ARTV) announce on August 6, 2026?
Artiva Biotherapeutics announced that it issued a press release reporting its financial results for the quarter ended June 30, 2026, and made that press release available as Exhibit 99.1 under the Exchange Act.
Which period do the ARTV financial results relate to?
The reported financial results for Artiva Biotherapeutics relate to the quarter ended June 30, 2026. The company describes this period in a press release furnished as Exhibit 99.1 in connection with its current disclosure.
How did Artiva Biotherapeutics (ARTV) provide its Q2 2026 financial results?
Artiva Biotherapeutics provided its Q2 2026 financial results through a press release dated August 6, 2026. This press release is attached as Exhibit 99.1 and is treated as information furnished under the Exchange Act.
Is Artiva Biotherapeutics’ financial results press release deemed filed with the SEC?
The company states the financial results press release, including Exhibit 99.1, is furnished, not filed for purposes of Section 18 of the Exchange Act and is not automatically incorporated into other securities law documents unless explicitly designated.
What is Exhibit 99.1 in Artiva Biotherapeutics’ (ARTV) disclosure?
Exhibit 99.1 is the press release dated August 6, 2026 that announces Artiva Biotherapeutics’ financial results for the quarter ended June 30, 2026. It contains the detailed financial information referenced in the company’s current disclosure.
On which exchange is Artiva Biotherapeutics (ARTV) listed and what is its status?
Artiva Biotherapeutics’ common stock is listed on the Nasdaq Global Market under the symbol ARTV. The company also identifies itself as an emerging growth company under applicable securities regulations.